Alzheimer's drug trials adopt cancer's multi-target approach

Norsk Bokmål

Alzheimer's trials are shifting to a multi-target approach inspired by cancer research, even after failures with Novo Nordisk's semaglutide. Only two drugs, Eli Lilly's Kisunla and Eisai and Biogen's Leqembi, are widely approved to slow progression. This evolution treats the brain-wasting disease as a complex system, seeking new ways to halt it amid its global impact.

Alzheimer's disease causes about 60% of the over 55 million global dementia cases, marked by amyloid and tau protein buildup in the brain.

Just two drugs are widely approved to slow its advance: Eli Lilly's Kisunla and Leqembi from Eisai and Biogen. Both reduce progression by roughly 30% through removal of toxic amyloid plaques.

Experts highlight a pivotal shift in trials, exemplified by the unsuccessful testing of Novo Nordisk's blockbuster GLP-1 drug semaglutide for Alzheimer's. These efforts underscore viewing the brain-wasting condition as a network of complex pathways, akin to recent transformations in cancer therapeutics.

Adopting cancer's multi-target playbook, researchers are advancing to pinpoint additional targets and methods for arresting the disease more comprehensively.

Relaterte artikler

Researcher analyzing brain MRI scans related to Alzheimer's drug lecanemab study, showing amyloid clearance but no glymphatic improvement.
Bilde generert av AI

Study finds lecanemab clears amyloid but shows no short-term recovery in brain waste-clearance system

Rapportert av AI Bilde generert av AI Faktasjekket

Researchers at Osaka Metropolitan University report that while the Alzheimer’s drug lecanemab reduces amyloid plaques, MRI measures found no improvement in the brain’s glymphatic waste-clearance three months after treatment began, underscoring the disease’s complexity and the need for multi-target approaches.

Anvisa approves lecanemabe for early-stage Alzheimer's treatment

Brazil's National Health Surveillance Agency (Anvisa) approved the drug lecanemabe, marketed as Leqembi, on Thursday, January 8, for patients with early-stage Alzheimer's. The monoclonal antibody, administered via infusion, slows disease progression in individuals with mild cognitive impairment and confirmed beta-amyloid protein in the brain. The approval marks progress, though it is not a cure.

SciNeuro and Novartis sign $1.7 billion Alzheimer's drug deal

Rapportert av AI

Chinese biotech firm SciNeuro Pharmaceuticals has partnered with Swiss pharmaceutical giant Novartis in a deal worth nearly $1.7 billion to develop treatments for Alzheimer's disease, which affects some 55 million people worldwide. The agreement grants Novartis exclusive worldwide rights to develop and commercialise SciNeuro's antibody candidates for the progressive brain disease. SciNeuro's novel amyloid beta-targeted antibody programme leverages proprietary blood-brain barrier shuttle technology to help more of the drug cross into the brain where Alzheimer's damage occurs.

Helse

Researchers develop nanoparticles to target disease proteins

Helse

Gene therapy slows Huntington’s disease progression by 75 percent

Helse

AI tool maps causal gene-control networks in Alzheimer’s brain cells

CAR T-cell therapy may slow ALS progression

Researchers are exploring CAR T-cell therapy to slow the advancement of amyotrophic lateral sclerosis (ALS) by targeting overactive immune cells in the brain. The approach aims to reduce neuron damage without curing the disease. Early studies suggest potential benefits for other neurodegenerative conditions as well.

Ny studie gir håp for vekttapsmedisiner mot alkoholisme

Rapportert av AI

Et nytt studie fra Universitetet i Göteborg viser at tirzepatid, det aktive virkestoffet i diabetes- og vekttapsmedisinen Mounjaro, reduserer alkoholforbruk og tilbakefalls-lignende atferd hos rotter og mus. Dette bygger på tidligere forskning på semaglutid i Ozempic og Wegovy, som demper alkoholforbruk hos mennesker. Forskere håper på lignende effekter hos pasienter med alkoholavhengighet.

MIT and Stanford create tool to expose cancer to immune system

Researchers from MIT and Stanford University have developed multifunctional molecules called AbLecs to block sugar-based immune checkpoints on cancer cells. This approach aims to enhance immunotherapy by allowing immune cells to better target tumors. Early tests in cells and mice show promising results in boosting anti-tumor responses.

Digital biomarkers can change dementia tracking: IISc professor

Rapportert av AI

Prof KVS Hari, director of the Centre for Brain Research at IISc Bengaluru, emphasized digital biomarkers for early detection and prevention of dementia. He noted that India's rapidly aging population makes dementia a major public health challenge. The centre focuses on data collection and AI to understand disease progression in the Indian context.

torsdag, 12. mars 2026, 21:43

New blood test spots Alzheimer's via protein shape changes

torsdag, 5. mars 2026, 12:55

Study links Alzheimer's origins to peripheral inflammation

onsdag, 4. mars 2026, 20:11

Scientists discover brain's tau cleanup system for Alzheimer's

onsdag, 18. februar 2026, 21:35

Experts flag shingles vaccine, sildenafil and riluzole as leading Alzheimer’s repurposing candidates

mandag, 26. januar 2026, 22:26

Study reveals Alzheimer's synapse loss via shared molecular pathway

lørdag, 10. januar 2026, 10:09

Flere rammet av hukommelsesykdommer i aldrende samfunn

onsdag, 24. desember 2025, 13:01

Scientists reverse advanced Alzheimer's in mice by restoring brain energy

mandag, 22. desember 2025, 21:11

Experimental drug NU-9 targets early Alzheimer's damage in mice

torsdag, 18. desember 2025, 01:14

Scientists identify new dementia affecting millions of elderly

onsdag, 19. november 2025, 16:42

Brazilian copper-targeting compound reverses Alzheimer’s-like deficits in rats

 

 

 

Dette nettstedet bruker informasjonskapsler

Vi bruker informasjonskapsler for analyse for å forbedre nettstedet vårt. Les vår personvernerklæring for mer informasjon.
Avvis